checkAd

     823  0 Kommentare Sanofi and Innate Pharma Collaborate on New Bispecific NK Cell Engagers in Immuno-Oncology

    Sanofi and Innate Pharma Collaborate
    on New Bispecific NK Cell Engagers in Immuno-Oncology

    - Research collaboration and licensing agreement for new bispecific antibodies using Innate Pharma's technology and Sanofi's technology and tumor targets -

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Sanofi S.A.!
    Long
    84,68€
    Basispreis
    0,65
    Ask
    × 13,97
    Hebel
    Short
    98,33€
    Basispreis
    0,82
    Ask
    × 11,10
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    - Innate Pharma eligible for up to €400m in milestones as well as royalties on net sales -

    Paris and Marseille, France - January 11, 2016 - Sanofi and Innate Pharma today announced that they have entered into a research collaboration and licensing agreement to apply Innate Pharma's new proprietary technology to the development of innovative bispecific antibody formats engaging natural killer (NK) cells to kill tumor cells through the activating receptor NKp46.

    Sanofi and Innate Pharma will work together on the generation and evaluation of up to two bispecific NK cell engagers, using technology from Innate Pharma and Sanofi's proprietary bispecific antibody format as well as tumor targets. Under the terms of the license agreement, Sanofi will be responsible for the development, manufacturing and commercialization of products resulting from the research collaboration. Innate Pharma will be eligible to up to €400m in development and commercial milestone payments as well as royalties on net sales.

    "Over the past year, Sanofi has launched strategic corporate collaborations in the field of immuno-oncology that exemplify our commitment to open innovation in R&D and have the potential to transform the treatment of cancer," said Gary Nabel, Chief Scientific Officer, Sanofi. "Working with Innate Pharma, we seek to create new bispecific antibodies that will focus the immune system to kill cancer cells by engaging natural killer cells."

    "There is a lot of excitement around bispecifics in immuno-oncology. By building on our knowledge of the activating receptor NKp46, we have generated a technology to specifically induce tumor killing by NK cells. This new technology platform is complementary to our innovative portfolio of first-in-class antibodies targeting immune checkpoints. We intend to use it for our internal portfolio expansion, as well as through non-exclusive agreements with other companies, such as in this agreement with Sanofi", said Nicolai Wagtmann, Chief Scientific Officer of Innate Pharma.

    Seite 1 von 4


    Diskutieren Sie über die enthaltenen Werte


    GlobeNewswire
    0 Follower
    Autor folgen

    Verfasst von GlobeNewswire
    Sanofi and Innate Pharma Collaborate on New Bispecific NK Cell Engagers in Immuno-Oncology Sanofi and Innate Pharma Collaborate on New Bispecific NK Cell Engagers in Immuno-Oncology - Research collaboration and licensing agreement for new bispecific antibodies using Innate Pharma's technology and Sanofi's technology and tumor targets - …

    Schreibe Deinen Kommentar

    Disclaimer